When Should Therapeutic Drug Monitoring Be Used for IBD Biologics?

Answer in brief: Therapeutic drug monitoring (TDM) is most established when a patient on anti-TNF therapy has active IBD or secondary loss of response. Drug concentration and anti-drug antibodies can help distinguish underexposure, immunogenicity and mechanistic failure. Routine proactive TDM in every stable patient remains more controversial and depends on the drug, setting and local practice.

Use TDM to answer a clinical question

A drug level is most useful when it changes management. In a patient with objective inflammation despite therapy, reactive TDM can help determine whether to intensify the same agent, address immunogenicity, or switch mechanism.

Interpret low drug levels in context

A low trough without significant antibodies suggests pharmacokinetic underexposure and may respond to dose intensification. Low drug with high anti-drug antibodies suggests immunogenicity; depending on antibody magnitude and clinical context, switching within or outside class and considering an immunomodulator may be appropriate. Adequate drug exposure with active inflammation points toward mechanistic failure rather than simply insufficient dose.

Confirm active inflammation first

Do not order TDM reflexively for every symptom. Diarrhea or pain may come from IBS, infection, bile-acid malabsorption, fibrosis or other causes. Establish objective inflammatory activity before interpreting a “low level” as the explanation.

Evidence varies across biologic classes

The best-developed thresholds and algorithms are for anti-TNF therapy. Exposure-response relationships exist for other biologics, but validated targets and management algorithms are less uniform. Assay methodology, timing and disease phenotype also affect interpretation.

TDM complements clinical judgment

Drug levels are not pass/fail numbers. The same concentration can have different meaning in severe fistulizing disease, mild luminal disease or a patient who already has endoscopic healing.

What trainees should remember

Reactive TDM is a problem-solving tool: confirm inflammation, measure exposure and antibodies, and use the pattern to distinguish underdosing, immunogenicity and mechanistic failure.

Frequently asked questions

Should every stable anti-TNF patient have routine trough levels?

Evidence for universal proactive monitoring remains less settled than for reactive TDM. Some centres use it selectively in high-risk patients.

Can TDM diagnose active IBD?

No. It explains treatment exposure; activity still needs clinical and objective assessment.

References and further reading

1. Thomson ABR. Clinical Pharmacology, Physiology and Pathophysiology: Gastroenterology, Hepatology, and Pancreaticobiliary Disorders. CAPstone Academic Publishers; 2024.

2. Thomson ABR. Guideline-Based Management in Gastroenterology. CAPstone Academic Publishers; 2015.

3. Feuerstein JD, et al. AGA Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Gastroenterology. 2017.

4. Lichtenstein GR, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2025.